Drug Profile


Alternative Names: CI 1041; CO 200461; PD 196860

Latest Information Update: 06 Aug 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Class Analgesics; Antiepileptic drugs; Antiparkinsonians; Neuroprotectants; Small molecules
  • Mechanism of Action NR2B N-Methyl-D-Aspartate antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Neuropathic pain; Pain; Parkinson's disease

Most Recent Events

  • 21 Nov 2002 No development reported - Phase-I for Neuropathic pain in USA (unspecified route)
  • 21 Nov 2002 No development reported - Phase-I for Pain in USA (unspecified route)
  • 28 Nov 2001 A preclinical study has been added to the adverse events and Parkinson's Disease pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top